been separated and isolated by means of chromatography in columns of 'Sephadex' gel. In a single experiment, mice were injected subcutaneously with this fraction (5·4 μg/g) dissolved in isotonic saline containing 0·01 normal formic acid. One day later, the mice were exposed to an X-ray dose of 850 r. Thirty days after irradiation 57 per cent of the mice so treated were still alive, while all the irradiated control mice injected with saline-formic acid had died.

At least three mechanisms may be invoked to account for the radioprotective effect of bee venom reported here for mice: (1) that it has a stressor-like action, thereby eliciting an "adaptation syndrome", assumed to increase radioresistance; (2) that it produces changes in the haemopoietic system, for example analogous to the effect of urethane[4] or of certain bacterial endotoxins[1]; (3) that it has antibacterial properties[13]. These mechanisms are now being investigated and further experiments are being carried out to separate, purify and identify the biologically active constituents of bee venom.

WILLIAM H. SHIPMAN

Nuclear Technology Division,

LEONARD J. COLE

Biological and Medical Sciences Division,
US Naval Radiological Defense Laboratory,
San Francisco, California.

Received March 31; revised May 26, 1967.

[1] Straube, R. L., Patt, H. M., Swift, M. N., *Amer. J. Physiol.*, **155**, 471 (1948).
[2] Smith, W. W., Alderman, I. M., and Gillespie, R. F., *Amer. J. Physiol.*, **191**, 124 (1957).
[3] Smith, W. W., *Science*, **127**, 340 (1958).
[4] Cole, L. J., and Gospe, S. R., *Radiat. Res.*, **15**, 684 (1961).
[5] Bacq, Z. M., and Alexander, P., *Fundamentals of Radiobiology*, second ed. (Pergamon Press, New York, 1961).
[6] Selye, H., *The Physiology and Pathology and Exposure to Stress* (Acta Inc., Montreal, 1950), supplements 1951 and 1952.
[7] Betz, E. H., *Contribution à l'Etude du Syndrome Endocrinien Provoque par l'Irradiation Totale de l'Organisme* (Masson, Paris, 1956).
[8] Doery, H. M., and Pearson, J. E., *Biochem. J.*, **92**, 599 (1964).
[9] Barker, S. H., Bayyuk, S. I., Brimacombe, J. S., and Palmer, D. J., *Nature*, **199**, 693 (1963).
[10] Kreil, G., *Monatsh. Chem.*, **96**, 2061 (1965).
[11] Haberman, E., and Reiz, K. G., *Biochem. Z.*, **341**, 451 (1965).
[12] Bacq, Z. M., *Chemical Protection Against Ionizing Radiation* (Charles C. Thomas, Springfield, Ill., 1965).
[13] Ortel, von S., and Markwardt, F., *Pharmazie*, **10**, 743 (1955).

MICROBIOLOGY

Tetramethyldipicrylamine—a New Antibacterial Agent

Moore, Meyer and Hudson recently reported on a new analytical reagent, tetramethyldipicrylamine (3,3′,5,5′-tetramethyl - 2,2′,4,4′,6,6′ - hexanitrodiphenylamine) and recommended it for further study in the analytical chemistry of the alkali metals[1]. A routine screening of this reagent by the National Cancer Institute, US National Institutes of Health, later showed its capacity to bring about a small but significant inhibition of tumour growth. A further check of its biological activity was then carried out, and is described here. The results indicate that this compound has antibacterial activity against Gram-positive organisms and several strains of sulphadiazine-resistant *Neisseria meningitidis*.

The sodium salt of tetramethyldipicrylamine was incorporated into trypticase soy broth and 1·5 per cent agar to give a final concentration of 10 and 50 μg/ml. medium. The following organisms were inhibited at the 10 μg/ml. concentration: *Staphylococcus aureus* (FDA-2098), *Staphylococcus epidermidis* (FDA-1200), *Streptococcus mitis*, *Streptococcus salivarius*, *Bacillus subtilis*, *Bacillus stereothermophilis* (NIII-7953). The following organisms were not inhibited at 50 μg/ml. concentration: *Pseudomonas aeruginosa*, *Proteus mirabilis*, *Proteus vulgaris*, *Salmonella heidelberg*, *Serratia marcescens* (ATCC-13880), *Escherichia coli*, *Salmonella montevideo*.

Fourteen strains of *Neisseria meningitidis*, including both sulphadiazine resistant and sensitive organisms of group *B* and *C*, were tested. The assay was carried out on Mueller–Hinton agar as described by Frank, Wilcox and Finland[2]. The minimal inhibitory concentration ranged from 0·06 to 0·5 μg of the compound/ml. of medium.

Using the serial dilution assay method, *Bacillus subtilis* was inhibited by the compound at 1 μg/ml. and *Diplococcus pneumoniae* at 2–5 μg/ml. (Muir, R. D., personal communication).

A Gram-negative plant pathogenic bacterium *Erwinia* species and the fungi *Candida albicans* and *Fusarium* species were tested by an agar diffusion method. The compound was only slightly active against *Erwinia* species and had no activity against the fungi in this test.

No inhibition was found in tests using the nematode *Turbatrix aceti* or the protozoan *Trichomonas foetus* (Muir, R. D., personal communication).

These results show high activity *in vitro* against Gram-positive organisms and little or no activity against most Gram-negative organisms, fungi, nematodes and protozoa. It is interesting, however, to note that the compound shows high activity against the Gram-negative sulphadiazine-resistant meningococcal strains.

The compound, which is acidic and of low solubility, forms well defined salts. The sodium salt is readily soluble and was used for all our tests. The free acid showed no antibacterial activity.

We thank Dr R. D. Muir of G. D. Searle and Co. for performing some of the microbiological tests.

THOMAS S. MEYER

Naval Dental Research Institute,
Naval Training Center,
Great Lakes, Illinois.

CARL E. MOORE

Department of Chemistry,
Loyola University of Chicago,
Chicago, Illinois.

PAUL F. FRANK*

Naval Medical Research Unit No. 4,
Great Lakes, Illinois.

Received April 17, 1967.

* Deceased.

[1] Moore, C. E., Meyer, T. S., and Hudson, J. W., *Talanta*, **13**, 171 (1966).
[2] Frank, P. F., Wilcox, C., and Finland, M. *J. Lab. Clin. Med.*, **35**, 188 (1950).

Ultrastructural Localization of Coxsackie B_4 Virus in Mouse Myocardium

COXSACKIE viral infections are known to cause myocardial lesions in various animal species[1]. The identification and localization of the Coxsackie viral particles in the heart have not been adequately demonstrated because of the absence of morphological criteria which will differentiate virus particles from glycogen granules and ribosomes. This communication describes the ultrastructural localization of Coxsackie B_4 virus particles in the mouse heart by a ferritin antibody technique.

A randomly selected litter of 5 day old suckling mice of *HaM/ICR* strain was inoculated intraperitoneally with 0·1 ml. of fluid containing 10^5 $TCID_{50}$ Coxsackie virus B_4 in monkey kidney cells; this strain was originally recovered by Kibrick and Benirschke from a 10 day old infant who died of encephalohepatomyocarditis[2]. The mice were killed 6 days after inoculation. Multiple 0·5 mm cubic blocks of tissue were cut from the myocardial wall and fixed in 4 per cent buffered glutaraldehyde for 20 min. The tissue blocks were washed in phosphate buffered normal saline, immediately immersed in a ferritin conjugated anti-Coxsackie virus B_4 rabbit serum for 45 min,